Loading...
Chemical structure of RMC-6291

GC69822

RMC-6291

Also known as 1-[4-(dimethylamino)-4-methylpent-2-ynoyl]-N-[(2S)-1-[[(6S,8S,14S)-22-ethyl-21-[2-[(1S)-1-methoxyethyl]-3-pyridinyl]-18,18-dimethyl-9,15-dioxo-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]amino]-3-methyl-1-oxobutan-2-yl]-4-fluoro-N-methylpiperidine-4-carboxamide

RMC-6291 is an orally effective covalent inhibitor of KRASG12C(ON)· RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA)· Therefore, RMC-6291 blocks the signaling of KRASG12C(ON) by spatially obstructing the binding of RAS effectors· RMC-6291 produces profound and sustained inhibition of the RAS pathway activity in KRASG12C tumor models

ChemicalCAS2641998-63-0MW1012.26FormulaC55H78FN9O8
CAS number
2641998-63-0
Molecular weight
1012.26
Formula
C55H78FN9O8
Solubility
DMSO ： 100 mg/mL (98·79 mM; Need ultrasonic)
InChIKey
HJNFYLSFWYRSHS-CMZSUCOPSA-N
Catalogue number
GC69822
Brand
GLPBIO
Computed properties PubChem CID 156336120 · XLogP 5.6 · TPSA 171 Ų · H-bond donors 2
XLogP
5.6
TPSA
171 Ų
H-bond donors
2
H-bond acceptors
13
Rotatable bonds
11
Heavy atoms
73

SMILES CCN1C2=C3C=C(C=C2)N4CCO[C@H](C4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC=C6)[C@H](C)OC)(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)C7(CCN(CC7)C(=O)C#CC(C)(C)N(C)C)F

Computed descriptors from PubChem (CID 156336120), public domain. Identity cross-checked against the supplier's molecular formula and weight — verify before use.

Ordering in Israel

Lead time
Ships from the manufacturer to your lab in 8–14 business days; customs and cold chain handled by LABO Scientific.
Pricing
Quoted in ILS, excl. VAT. Add the item to your quote and we confirm the final price, usually the same business day.
Documents
Lot certificate of analysis and manufacturer SDS are emailed with your order confirmation.
Who we serve
Universities, hospitals and biotech companies across Israel. Research use only — not for diagnostic or therapeutic use.